Skip to main content
    A

    AbbVie Inc (ABBV)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $294.64
    -0.39 (-0.13%)

    Market Cap: $521.50B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    AbbVie Inc (ABBV) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect AbbVie (ABBV) to earn $13.98 per share in the fiscal year ending Dec 31, 2026, on revenue of $67.80B. Of 29 analysts, 23 rate the stock Buy or Strong Buy, 5 Hold and 1 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $16.20.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 29 ratings average 2.03, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 79% of the ratings.

    RatingAnalystsShare
    Strong Buy724.1%
    Buy1655.2%
    Hold517.2%
    Sell00.0%
    Strong Sell13.4%
    Consensus
    Buy
    Total analysts
    29

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 15.9% and revenue estimates rise 9.1%.

    Fiscal year ending Dec 31, 2026
    $13.98
    EPS consensus, revenue $67.80B
    Fiscal year ending Dec 31, 2027
    $16.20
    EPS consensus, revenue $73.94B
    Next report
    Feb 2, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$13.98$13.93 to $14.1328$67.80B$67.70B to $67.98B25
    Dec 31, 2027$16.20$15.31 to $17.2329$73.94B$71.98B to $75.96B25

    Quarterly Estimates

    The EPS consensus falls from $3.95 for the quarter ending Dec 31, 2026 to $3.44 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$3.95$3.73 to $4.2126$18.78B$17.96B to $19.40B25
    Mar 31, 2027$3.44$3.31 to $3.909$16.43B$15.89B to $17.20B6

    Estimate Revisions

    PeriodUp 30 daysDown 30 days
    Quarter ending Mar 31, 202730

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 0.2% from $14.01.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$13.98$13.99$13.97$14.01$14.01-0.2%
    Fiscal year ending Dec 31, 2027$16.20$16.18$16.22$16.27$16.28-0.5%
    Quarter ending Mar 31, 2027$3.44$3.33$3.34$3.34$3.34+2.8%

    Frequently Asked Questions About ABBV

    What is the ABBV stock forecast?

    Consensus analyst estimates put AbbVie's EPS at $13.98 for the fiscal year ending Dec 31, 2026, on revenue of $67.80B. The consensus rating from 29 analysts is Buy.

    How do analysts rate ABBV stock?

    Of 29 analysts covering AbbVie, 7 rate it Strong Buy, 16 Buy, 5 Hold, 0 Sell and 1 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from ABBV next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $13.98, with estimates from $13.93 to $14.13 from 28 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $16.20, with estimates from $15.31 to $17.23 from 29 analysts.

    What revenue do analysts expect from AbbVie next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $67.80B, with estimates from $67.70B to $67.98B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $73.94B, with estimates from $71.98B to $75.96B.

    How many analysts cover ABBV?

    29 analysts rate AbbVie stock, and 28 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.